iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
New GS7977+GS5885 Studies/Phase 3
 
 
  New in phase 3 & recruiting: Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV......Multicenter, Randomized, Open-Label......Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection......Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV........http://clinicaltrials.gov/ct2/show/NCT01701401?term=gs-5885&rank=2
 
This new study is recruiting: Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects.....phase 2.....8 or 12 weeks therapy.....in subjects who had previously received a regimen containing a protease inhibitor for the treatment of HCV.....Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects......http://clinicaltrials.gov/ct2/show/NCT01726517?term=gs-5885&rank=1 		 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org